Your browser doesn't support javascript.
loading
Mediterranean diet and antihypertensive drug use: a randomized controlled trial.
Ribó-Coll, Margarita; Lassale, Camille; Sacanella, Emilio; Ros, Emilio; Toledo, Estefanía; Sorlí, José V; Babio, Nancy; Lapetra, José; Gómez-Gracia, Enrique; Alonso-Gómez, Ángel M; Fiol, Miquel; Serra-Majem, Lluis; Pinto, Xavier; Castañer, Olga; Díez-Espino, Javier; González, José I; Becerra-Tomás, Nerea; Cofán, Montserrat; Díaz-López, Andrés; Estruch, Ramón; Hernáez, Álvaro.
Afiliación
  • Ribó-Coll M; Cardiovascular Risk, Nutrition, and Aging Research Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS).
  • Lassale C; PhD program in Food Science and Nutrition, Faculty of Pharmacy and Food Science, Universitat de Barcelona, Barcelona.
  • Sacanella E; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid.
  • Ros E; Cardiovascular Risk and Nutrition Research Group, Hospital del Mar Medical Research Institute (IMIM).
  • Toledo E; Cardiovascular Risk, Nutrition, and Aging Research Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS).
  • Sorlí JV; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid.
  • Babio N; Internal Medicine Service, Hospital Clínic.
  • Lapetra J; Cardiovascular Risk, Nutrition, and Aging Research Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS).
  • Gómez-Gracia E; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid.
  • Alonso-Gómez ÁM; Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clínic, Barcelona.
  • Fiol M; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid.
  • Serra-Majem L; Department of Preventive Medicine and Public Health, Universidad de Navarra, Pamplona.
  • Pinto X; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid.
  • Castañer O; Department of Preventive Medicine and Public Health, Universidad de Valencia, Valencia.
  • Díez-Espino J; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid.
  • González JI; Unitat de Nutrició Humana, Departament de Bioquimica i Biotecnologia, Universitat Rovira i Virgili.
  • Becerra-Tomás N; Institut d'Investigació Pere Virgili (IISPV), Hospital Universitari Sant Joan de Reus, Reus.
  • Cofán M; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid.
  • Díaz-López A; Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Sevilla.
  • Estruch R; Consorcio CIBER, M.P. Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid.
  • Hernáez Á; Department of Preventive Medicine and Public Health, Universidad de Málaga, Málaga.
J Hypertens ; 39(6): 1230-1237, 2021 06 01.
Article en En | MEDLINE | ID: mdl-33496530
ABSTRACT

OBJECTIVE:

To examine in older individuals at high cardiovascular risk whether following a Mediterranean diet decreased the necessity of antihypertensive drugs and modulated their associated cardiovascular risk.

METHODS:

In the PREvención con DIeta MEDiterránea study, we assessed whether volunteers randomly allocated to an intervention with a Mediterranean diet enriched with extra-virgin olive oil or nuts (relative to a low-fat control diet) disclosed differences in the risk of initiating antihypertensive medication in nonusers at baseline (n = 2188); and escalating therapy in participants using one, two, or three drugs at baseline (n = 2361, n = 1579, and n = 554, respectively). We also assessed whether allocation to Mediterranean diet modified the association between antihypertensive drug use and incident cardiovascular events.

RESULTS:

Participants allocated to Mediterranean diet interventions were associated with lower risk of initiating antihypertensive therapy [5-year incidence rates 47.1% in the control diet, 43.0% in MedDiets; hazard ratio = 0.84, 95% CI (0.74--0.97), in a model adjusted for age, sex, and recruitment site]. Volunteers using two drugs at baseline in the Mediterranean diet intervention enriched with extra-virgin olive oil decreased their risk of therapy escalation [5-year incidence rates 22.9% in the control diet, 20.1% in the MedDiet; hazard ratio = 0.77, 95% CI (0.60--0.99)]. Allocation to Mediterranean diet interventions attenuated the association between antihypertensive therapy at baseline and incidence of major adverse cardiovascular events (P interaction = 0.003).

CONCLUSION:

In an older population at high cardiovascular risk, following a Mediterranean diet reduced the risk of initiating or escalating antihypertensive medication and attenuated cardiovascular risk in antihypertensive drug users.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Dieta Mediterránea Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: J Hypertens Año: 2021 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Cardiovasculares / Dieta Mediterránea Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans Idioma: En Revista: J Hypertens Año: 2021 Tipo del documento: Article
...